A Randomized Controlled Trial of the Impact of ICCAN on Cancer Treatment Completion and Quality of Life

Inclusion Criteria:

- fluent in English, Spanish, or Mandarin

- between the ages of 21-80 years old

- In the Investigator's judgment, participants must have satisfactory cognitive
function to provide valid informed consent and participate in the ICCAN intervention.
The Blessed Orientation-Memory Concentration test (BOMC) will be used as a cognitive
screening tool. Patients must have a BOMC score of less than or equal to 11.

- has a new diagnosis of either breast, colon or lung cancer (diagnosed within the past
month) currently receiving chemotherapy (started within the past month) and/or
radiation therapy (started within the past week), or

- scheduled to begin chemotherapy and/or radiation therapy within the next 2 months
(excluding surgery only patients)

- planning on remaining in the area for at least 1 year

Exclusion Criteria:

- diagnosed with Stage IV disease

- presence of cognitive impairment disorder (e.g., delirium or dementia) sufficient to
preclude meaningful informed consent and/or data collection. (BOMC >11).

- has another family member already enrolled in ICCAN (as determined by patient report)